Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 5, 2006, Pages 702-710

  Aubin, Marie Claude ^a   Carrier, Michel ^a   Shi, Yan Fen ^a   Tardif, Jean Claude ^a   Perrault, Louis P ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Antioxidants; Arteries; Endothelium derived relaxing factor; Heart; Hypertrophy; Oxidative stress

Indexed keywords

ANGIOTENSIN II; CYCLIC GMP; HYDROPEROXIDE; NITRATE; NITRIC OXIDE; NITRITE; PLACEBO; PROBUCOL; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; ARTERY LIGATION; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; BLOOD VESSEL REACTIVITY; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EPICARDIUM; EVALUATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HISTOLOGY; LIPID BLOOD LEVEL; MALE; NONHUMAN; OBSERVATION; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; SWINE; TREATMENT OUTCOME; VASODILATATION;

EID: 33748137237     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211763.13894.87     Document Type: Article

References (23)

1. Fareh J, Touyz RM, Schiffrin EL, et al. Endothelin-1 and angiotensin II receptors in cells from rat hypertrophied heart. Circ Res. 1996;78:302-311.
2. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation. 1987;75:I26-33.
3. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140:848-856.
4. Grieve DJ, MacCarthy PA, Gall NP, et al. Divergent biological actions of coronary endothelial nitric oxide during progression of cardiac hypertrophy. Hypertension. 2001;38:267-273.
5. Lüscher TF, Noll G. Endothelial dysfunction in the coronary circulation. J Cardiovasc Pharmacol. 1994;24:S16-26.
6. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993;87:86-93.
7. Wattanapitayakul SK, Weinstein DM, Holycross BJ. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J. 2000;14:271-278.
8. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
9. Nakagami H, Takemoto M, Liao JK. NADPH oxidase derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003;35:851-859.
10. Malo O, Carrier M, Shi YF, et al. Specific alterations of endothelial signal transduction pathways of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2003;42:275-286.
11. B and release of COX-derived products contribute to endothelial dysfunction in porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2005;6:499-508.
12. Malo O, Desjardins F, Tanguay JF, et al. Tetrahydrobiopterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model. Cardiovasc Res. 2003;59:501-511.
13. Cote G, Tardif JC, Lespérance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty, Multivitamins and Protocol Study Group. Circulation. 1999;99:30-35.
14. Yokoyama T, Miyauchi K, Kutara T, et al. Effect of probucol on neointimal thickening in a stent porcine model of restenosis. Jpn Heart J. 2004;45:305-313.
15. Li JM, Gall NP, Grieve DJ, et al. Activation of NAD(P)H oxidase during progression of cardiac hypertrophy to heart failure. Hypertension. 2002;40:477-484.
16. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP. Circ Res. 1983;52:352-357.
17. Sia YT, Lapointe N, Parker TG, et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation. 2002;105:2549-2555.
18. Inoue N, Ohara Y, Fukai T, et al. Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. Am J Med Sci. 1998;315:242-247.
19. Ramasamy S, Drummond GR, Ahn J, et al. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Mol Pharmacol. 1999;56:116-123.
20. Weiss N, Zhang YY, Heydrick S, et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelia dysfunction. Proc Natl Acad Sci U S A. 2001;98:12503-12508.
21. Stuehr D, Pou S, Rosen GM. Oxygen reduction by nitric oxide synthases. J Biol Chem. 2001;276:14533-14536.
22. Bouloumie A, Bauersachs J, Linz W, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30:934-941.
23. Nakamura R, Egashira K, Machida Y, et al. A. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation. 2002;106:362-367.